Indian stocks: Visit www.stage2stocks.com →

Eton Pharmaceuticals, Inc.

Stage 2 · Advancing · week 30

As of Oct 22, 2026, Eton Pharmaceuticals is in Stage 2, the uptrend phase, now in week 30 (since Mar 23, 2026). It closed at $50.02, 22.4% below its 52-week high and above its 200-day average, which is rising.

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. More about the company

$50.02
+1.46% today
$1.4B · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care

Is ETON early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 17w
S2 30w
S2 31w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 2w → S1 1w → S2 10w → S3 7w → S2 11w → S3 4w → S4 17w → S1 4w → S2 30w → S3 5w → S2 9w → S3 7w → S2 12w → S3 7w → S4 6w → S1 3w → S2 31w current
Total tracked: 165 weeks across 17 stage runs.

ETON among Drug Manufacturers - Specialty & Generic2nd of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
vs 52W High
-22.4%
$14.35 lo$64.43 hi
22.4% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 30
1w13w26w
Week 30, mature
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
44.4%
200 DMA: $34.64 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.79x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-10.1%
3M
+17.4%
6M
+117.8%
YTD
+207.6%
1Y
+169.6%
Scan Membership
Breakout Watch
Latest: 2025-05-15
8 appearances in last 60 days. First seen: 2020-02-04.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 30 · Vol 0.79x
2026-10-21S2
Wk 30 · Vol 0.48x
2026-10-20S2
Wk 30 · Vol 0.52x
2026-10-19S2
Wk 30 · Vol 0.61x
2026-10-16S2
Wk 29 · Vol 0.76x
2026-10-15S2
Wk 29 · Vol 0.75x
2026-10-14S2
Wk 29 · Vol 0.72x
2026-10-13S2
Wk 29 · Vol 0.90x
2026-10-12S2
Wk 29 · Vol 0.71x
2026-10-09S2
Wk 28 · Vol 0.60x
2026-10-08S2
Wk 28 · Vol 0.88x
2026-10-07S2
Wk 28 · Vol 1.25x
Moving averages & range
50 DMA
$56.75
200 DMA
$34.64
52W High
$64.43
52W Low
$14.35
5D Low
$49.22
Resistance levels (recent highs)
20d High
$59.19
60d High
$64.43
120d High
$64.43
250d High
$64.43
Next resistance
+18.3%
to 20d High
P/E (TTM)
125.0
Forward 19.6
ROE
+36.0%
Profit margin +12.0%
Dividend Yield
0.00%
P/B 30.4

Eton Pharmaceuticals: quick answers

What stage is Eton Pharmaceuticals in?

As of Oct 22, 2026, Eton Pharmaceuticals (ETON) is in Stage 2, the uptrend phase. It entered Stage 2 on Mar 23, 2026 and is in week 30. What the four stages mean

Is Eton Pharmaceuticals in an uptrend?

Yes. Eton Pharmaceuticals is in a Stage 2 uptrend. It trades 44.4% above its 200-day average, which is rising.

How far is Eton Pharmaceuticals from its 52-week high?

Eton Pharmaceuticals closed at $50.02 on Oct 22, 2026, 22.4% below its 52-week high of $64.43. Its 52-week low is $14.35.

How has Eton Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Eton Pharmaceuticals is up 169.6% over the past year and up 207.6% so far in 2026.

Which sector and industry is Eton Pharmaceuticals in?

Eton Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.